GTN
GTN helps pharmaceutical researchers find novel drug-like molecules faster and at lower development cost. It uses a patented Generative Tensorial Networks approach that combines quantum physics principles with machine learning to simulate, filter, and search vast chemical spaces. The platform leverages quantum machine learning and molecular simulation techniques to surface candidates that conventional methods miss and integrates with drug discovery workflows for R&D teams. GTN targets pharmaceutical and biotech companies aiming to reduce time and cost in early-stage drug discovery.
GTN
GTN helps pharmaceutical researchers find novel drug-like molecules faster and at lower development cost. It uses a patented Generative Tensorial Networks approach that combines quantum physics principles with machine learning to simulate, filter, and search vast chemical spaces. The platform leverages quantum machine learning and molecular simulation techniques to surface candidates that conventional methods miss and integrates with drug discovery workflows for R&D teams. GTN targets pharmaceutical and biotech companies aiming to reduce time and cost in early-stage drug discovery.
TL;DR
What they do: Quantum machine learning platform for drug discovery (Generative Tensorial Networks)
Founded: 2017
Headquarters: London, United Kingdom
Target customers: Pharmaceutical and biotech R&D teams
Total disclosed funding: USD 2,841,313 (seed-stage, last recorded 2018-11-01)
Company Overview
Problem Domain
Early-stage drug discovery: identifying novel drug-like molecules and reducing time/cost of candidate identification.
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
USD 2,841,313
Investor Signal
“Investors include AI Seed, Entrepreneurs First, Google for Startups, Isomer Capital, Octopus Ventures, Pentech Ventures”